This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.
Obesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.
In this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:
* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels * Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels * Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS) * Anthropometric measurements: body weight, height, waist and hip circumference, BMI * Nutritional intake: 3-day dietary records
The study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.
Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month
Aged between 19-50 years
BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities
Signed informed consent form
Did not undergo or is not planned to undergo LSG
Outside the age range of 19-50 years
Did not sign the informed consent form
BMI <40 kg/m² or BMI <35 kg/m² without obesity-related comorbidities
Adults with morbid obesity who underwent Laparoscopic Sleeve Gastrectomy (LSG) at Bursa Yıldırım Doruk Hospital General Surgery Clinic within the last month, meeting the inclusion criteria.
Cohort
Prospective
Clinical and Biochemical Assessment
Other interventionParticipants will undergo two assessment visits: at baseline (within 1 month post-surgery) and at 6-month follow-up. Each visit includes anthropometric measurements (body weight, height, waist and hip circumference, BMI), biochemical blood analysis (fasting glucose, lipid profile, insulin, zonulin, secretory IgA, LPS), gastrointestinal symptom evaluation via GSRS, and 3-day dietary records.
Change in Fasting Blood Glucose Concentration (mg/dL)
Change in serum fasting blood glucose levels after 12-hour fasting between baseline and 6-month follow-up.
Change in Total Cholesterol Concentration (mg/dL)
Change in serum total cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Change in Triglyceride Concentration (mg/dL)
Change in serum triglyceride levels after 12-hour fasting between baseline and 6-month follow-up.
Change in HDL Cholesterol Concentration (mg/dL)
Change in serum high-density lipoprotein (HDL) cholesterol levels after 12-hour fasting between baseline and 6-month follow-up.
Change in Body Weight (kg)
Change in body weight between baseline and 6-month follow-up.
Change in Body Mass Index (kg/m²)
Change in BMI between baseline and 6-month follow-up. Weight and height will be combined to report BMI in kg/m².
Change in Waist Circumference (cm)
Change in waist circumference between baseline and 6-month follow-up.
Change in Hip Circumference (cm)
Change in hip circumference between baseline and 6-month follow-up.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
